Companies / Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc.

Nasdaq: AVTXCIK 1534120WAYNE, PA

Financials · FY2025

Revenue$59.0K
Net income$-78.26M
Total debt$14.25M
Cash$85.38M
Diluted EPS$-5.84
Shares outstanding53.6M

Ownership

53.6M shares outstanding · as of Aug 3, 2026
0.23%Insiders
Ownership
Insiders0.23%122,234
10%+ / strategic14.04%7,530,926
Institutions41.42%22,213,948
Public float44.31%23,762,881

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 13

View all →
Insider% of sharesShares
Neil Garry ArthurCEOChief Executive Officer · Director
0.17%90,114
Sullivan Christopher RyanFormerChief Financial Officer
0.06%33,297
Chan MitchellDirector
0.01%6,333
Kantoff AaronDirector
0.01%6,333
Kaplan GillaDirector
0.01%6,333
Truex SamanthaDirector
0.01%6,333
Doyle MittieChief Medical Officer
<0.01%3,622
Goldman JonathanDirector
<0.01%3,166
Boyd TaylorChief Business Officer
——
Jain RitaDirector
——

Institutional holders 89

View all →
HolderValue% of shares
BlackRock, Inc.$80.68M8.14%
State Street Corporation$53.39M5.39%
Bvf INC/IL$24.38M3.04%
Nantahala Capital Management, LLC$22.43M2.30%
Affinity Asset Advisors, LLC$19.09M1.96%
Caligan Partners LP$16.01M1.64%
Vanguard Group Inc$14.60M1.50%
Adage Capital Partners Gp, L.L.C.$12.75M1.59%
Millennium Management LLC$12.47M1.56%
Point72 Asset Management, L.P.$11.40M1.17%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Mar 16, 2026Doyle Mittie
Executive
SellCommon Stock$411.6K-25K
-87.56%
3,622
<0.01% of shares
medium
Mar 28, 2026Neil Garry Arthur
CEO
OtherCommon Stock$304.1K-22K
-19.55%
90,114
0.17% of shares
low
Mar 16, 2026Doyle Mittie
Executive
ExerciseCommon Stock$246.7K+20K
+538.38%
23,122
0.04% of shares
low
Mar 28, 2026Sullivan Christopher Ryan
Executive
OtherCommon Stock$114.5K-8K
-19.84%
33,297
0.06% of shares
low
Mar 16, 2026Doyle Mittie
Executive
ExerciseCommon Stock$48.2K+6K
+25.91%
29,114
0.05% of shares
low
Jun 2, 2026Kaplan Gilla
Director
GrantStock Option (Right to Buy)—+20K
20,100
0.04% of shares
low
Mar 28, 2026Sullivan Christopher Ryan
Executive
ExerciseRestricted Stock Units—-24K
-50.00%
24,200
0.05% of shares
low
Mar 28, 2026Sullivan Christopher Ryan
Executive
ExerciseCommon Stock—+24K
+139.58%
41,538
0.08% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A—804,084—
Fmr LLCPassive13G/A—5,737,966—
State Street CorporationPassive13G—2,889,287—
Orbimed Advisors LLCPassive13G/A—1,187,300—
Balyasny Asset Management L.P.Passive13G/A———
Millennium Management LLCPassive13G———
Millennium Management LLCPassive13G———
Millennium Management LLCPassive13G———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
AVTX——05338F306—